IN2014DN05011A - - Google Patents

Download PDF

Info

Publication number
IN2014DN05011A
IN2014DN05011A IN5011DEN2014A IN2014DN05011A IN 2014DN05011 A IN2014DN05011 A IN 2014DN05011A IN 5011DEN2014 A IN5011DEN2014 A IN 5011DEN2014A IN 2014DN05011 A IN2014DN05011 A IN 2014DN05011A
Authority
IN
India
Prior art keywords
nmo
diagnosing
materials
methods
provides
Prior art date
Application number
Inventor
Vanda A Lennon
Thomas J Kryzer
Original Assignee
Mayo Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Foundation filed Critical Mayo Foundation
Publication of IN2014DN05011A publication Critical patent/IN2014DN05011A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

The present invention provides for methods and materials for diagnosing and treating neuromyelitis optica (NMO) and related disorders.
IN5011DEN2014 2003-11-25 2004-11-24 IN2014DN05011A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/723,180 US7101679B2 (en) 2003-11-25 2003-11-25 Marker for neuromyelitis optica
PCT/US2004/039710 WO2005051178A2 (en) 2003-11-25 2004-11-24 Marker for neuromyelitis optica

Publications (1)

Publication Number Publication Date
IN2014DN05011A true IN2014DN05011A (en) 2015-07-10

Family

ID=34592190

Family Applications (1)

Application Number Title Priority Date Filing Date
IN5011DEN2014 IN2014DN05011A (en) 2003-11-25 2004-11-24

Country Status (9)

Country Link
US (5) US7101679B2 (en)
EP (1) EP1700120B1 (en)
JP (1) JP4538464B2 (en)
CN (1) CN1910456B (en)
AT (1) ATE424560T1 (en)
DE (1) DE602004019812D1 (en)
ES (1) ES2320006T3 (en)
IN (1) IN2014DN05011A (en)
WO (1) WO2005051178A2 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101679B2 (en) 2003-11-25 2006-09-05 Mayo Foundation For Medical Education And Research Marker for neuromyelitis optica
US20070093673A1 (en) * 2005-10-24 2007-04-26 Andre Vachereau Boron-containing compounds, uses and preparation thereof
JP4273235B2 (en) * 2006-06-01 2009-06-03 国立大学法人 新潟大学 Aquaporin 4 inhibitor
WO2009039363A2 (en) * 2007-09-20 2009-03-26 Mayo Foundation For Medical Education And Research Neuromyelitis optica autoantibodies as a marker for neoplasia
JP5117336B2 (en) * 2008-09-18 2013-01-16 国立大学法人 千葉大学 Method for measuring test markers for multiple sclerosis or NMO
US9891219B2 (en) * 2008-10-10 2018-02-13 Mayo Foundation For Medical Education And Research Methods for treating neuromyelitis optica (NMO) by administration of eculizumab to an individual that is aquaporin-4 (AQP4)-IgG autoantibody positive
GR1007341B (en) 2010-04-21 2011-07-05 ΕΛΛΗΝΙΚΟ ΙΝΣΤΙΤΟΥΤΟ ΠΑΣΤΕΡ (κατά ποσοστό 40%), Diagnostic assay
RU2012149427A (en) * 2010-05-13 2014-06-20 Юниверсити Оф Медисин Энд Дентистри Оф Нью-Джерси PROFILES OF DIAGNOSTIC AUTOATITITIES FOR DETECTION AND DIAGNOSTIC OF NEURODEGENERATIVE DISEASES
DE102011011280A1 (en) * 2011-02-15 2012-08-16 Euroimmun Medizinische Labordiagnostika Ag Diagnostic kit and a method for examining a human patient sample for the presence of neuromyelitis optica-specific antibodies
WO2012145746A1 (en) * 2011-04-21 2012-10-26 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for the treatment of neuromyelitis optica
WO2013010003A1 (en) 2011-07-12 2013-01-17 University Of Medicine And Dentistry Of New Jersey Diagnostic biomarker profiles for the detection and diagnosis of alzheimer's disease
CN104040344A (en) * 2011-10-21 2014-09-10 德克萨斯系统大学评议委员会 Codon signature for neuromyelitis optica
EP2833140B1 (en) * 2012-03-30 2018-05-09 Konica Minolta, Inc. Method for detecting biological material
US20150139981A1 (en) * 2012-05-21 2015-05-21 The Regents Of The University Of California Enzymatic modification of anti-aqp4 autoantibody for modulating neuromyelitis optica
CN102898513B (en) * 2012-10-31 2016-03-16 徐俊 ELISpot optic neuromyelitis diagnostic kit and application thereof
WO2014154907A1 (en) 2013-03-28 2014-10-02 Protagen Ag Method for the diagnosis of neuromyelitis optica
WO2015179360A1 (en) * 2014-05-19 2015-11-26 The Johns Hopkins University Highly soluble aquaporin -4 extracelluar loop c peptide immunization for treatment of neuromyelitis optica
CN106661623A (en) * 2014-06-30 2017-05-10 西门子医疗有限公司 Diagnosis of neuromyelitis optica vs. multiple sclerosis using mirna biomarkers
CN104698190A (en) * 2015-03-16 2015-06-10 中国人民解放军总医院 Biological diagnosis marker for central nervous system demyelinating diseases
US10098935B2 (en) * 2015-05-01 2018-10-16 The Board Of Trustees Of The Leland Stanford Junior University Aquaporin tolerizing vaccines and methods of use thereof
US10912926B2 (en) * 2016-05-13 2021-02-09 C. R. Bard, Inc. Peripherally inserted central catheter systems, devices, and methods thereof for pediatrics
CN106318974A (en) * 2016-08-29 2017-01-11 南方医科大学南方医院 Cell immobilization technology and AQP4 antibody detection kit prepared through same
KR101977843B1 (en) 2017-02-16 2019-05-13 국립암센터 Biomarker for diagnosis of Neuromyelitis optica and Multiple sclerosis and Use thereof
WO2018190365A1 (en) * 2017-04-12 2018-10-18 国立大学法人九州大学 Neuropathic pain marker and use thereof
KR102089042B1 (en) * 2017-05-16 2020-03-13 서울대학교병원 Improved method for detecting anti-aquaporin 4 antibody using complement inactivation
CN108998450A (en) * 2018-08-08 2018-12-14 昆明医科大学第附属医院 Primer, cDNA, carrier, AQP4 monoclonal antibody and preparation method
CN110618264A (en) * 2019-09-10 2019-12-27 南方医科大学 Method for detecting anti-AQP 4 antibody based on quantum dot polystyrene microspheres
CN111272998A (en) * 2020-01-09 2020-06-12 天津天海新域生物科技有限公司 Method for simultaneously detecting central demyelinating autoantibodies AQP4, MOG and MBP
CN115232795B (en) * 2021-07-22 2023-09-19 北京和合医学诊断技术股份有限公司 Cell strain for stably expressing AQP4-M23 protein, construction method and application thereof
CN113358881B (en) * 2021-08-10 2021-11-30 首都医科大学附属北京天坛医院 Biomarker for NMOSD prediction or recurrence monitoring and application thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US37273A (en) * 1863-01-06 Improved canteen
US4708713A (en) * 1984-11-16 1987-11-24 Anisa Medical, Inc. Method and system for removing immunosuppressive components from the blood of mammals
US5258503A (en) * 1987-09-08 1993-11-02 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Autoantibody adsorbent and apparatus for removing autoantibodies using the same
US5614192A (en) * 1989-07-19 1997-03-25 Connective Therapeutics, Inc. T cell receptor peptides as therapeutics for immune-related disease
US5214136A (en) * 1990-02-20 1993-05-25 Gilead Sciences, Inc. Anthraquinone-derivatives oligonucleotides
US5218105A (en) * 1990-07-27 1993-06-08 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5741671A (en) * 1991-12-12 1998-04-21 The Johns Hopkins University Isolation cloning and expression of transmembrane water channel aquaporin 1(AQP1)
US5324638A (en) * 1992-05-13 1994-06-28 Sloan-Kettering Institute For Cancer Research Brain transcription factor, nucleic acids encoding same and uses thereof
DE4227695C1 (en) * 1992-08-21 1993-10-07 Fresenius Ag Centrifuge to separate blood into its components
US5676644A (en) 1995-06-07 1997-10-14 Cobe Laboratories, Inc. Extracorporeal blood processing methods and apparatus
AU1059897A (en) * 1995-11-09 1997-05-29 Trustees Of Boston University Dna comprising a neuron-specific transcriptional promoter and its use in a gene therapy vector
AU763929B2 (en) 1998-11-25 2003-08-07 Amarillo Biosciences, Inc. Interferon-alpha mediated upregulation of aquaporin expression
US20040014087A1 (en) 1999-06-01 2004-01-22 Incyte Corporation Molecules for diagnostics and therapeutics
US6409726B1 (en) * 1999-11-08 2002-06-25 Alan G. Ellman Electrosurgical instrument for ear surgery
US20030072737A1 (en) 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US20040048253A1 (en) 2001-02-21 2004-03-11 Panzer Scott R. Molecules for diagnostics and therapeutics
US7251568B2 (en) 2001-04-18 2007-07-31 Wyeth Methods and compositions for regulating bone and cartilage formation
US7026121B1 (en) 2001-06-08 2006-04-11 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
US20040115629A1 (en) 2002-01-09 2004-06-17 Panzer Scott R Molecules for diagnostics and therapeutics
DE10326526B4 (en) * 2002-06-22 2006-06-22 Spinner Gmbh Coaxial connector
US7101679B2 (en) 2003-11-25 2006-09-05 Mayo Foundation For Medical Education And Research Marker for neuromyelitis optica

Also Published As

Publication number Publication date
EP1700120B1 (en) 2009-03-04
WO2005051178A2 (en) 2005-06-09
CN1910456B (en) 2011-04-13
US20050112116A1 (en) 2005-05-26
JP4538464B2 (en) 2010-09-08
DE602004019812D1 (en) 2009-04-16
US20120219969A1 (en) 2012-08-30
US7101679B2 (en) 2006-09-05
US20080145870A1 (en) 2008-06-19
US7947254B2 (en) 2011-05-24
EP1700120A2 (en) 2006-09-13
JP2007518068A (en) 2007-07-05
US20140314796A1 (en) 2014-10-23
US8524508B2 (en) 2013-09-03
US20090143710A1 (en) 2009-06-04
ATE424560T1 (en) 2009-03-15
CN1910456A (en) 2007-02-07
ES2320006T3 (en) 2009-05-18
EP1700120A4 (en) 2007-11-14
WO2005051178A3 (en) 2005-12-29

Similar Documents

Publication Publication Date Title
IN2014DN05011A (en)
WO2002099054A3 (en) Hccss as modifiers of the p53 pathway and methods of use
MY143215A (en) Multifocal lenses for pre-presbyopic individuals
WO2003066802A3 (en) Gene expression analysis using nicking agents
AU2003284238A1 (en) Indentation hardness test system
SG170793A1 (en) Anti-mn antibodies and methods of using same
IL172646A0 (en) Antibodies against interleukin -22 and uses therefor
WO2001075178A3 (en) Methods for identifying peptide aptamers capable of altering a cell phenotype
IL174195A0 (en) Compositions, reagents and kits for and methods of diagnosing, monitoring and treating obesity and/or diabetes
WO2003104425A3 (en) Novel stable anti-cd22 antibodies
WO2005009434A3 (en) Compounds and methods for inducing apoptosis in cancer cells
WO2004053497A3 (en) Method for predicting the response to her2-directed therapy
TW200609559A (en) Contact lenses and methods for their design
TW200510398A (en) Novel compounds
WO2004083241A3 (en) Btc-interacting proteins and use thereof
WO2004045545A3 (en) Compositions and methods for the treatment of cancer, screening of putative anti-cancer compounds, and assessing cancer progression
AU2003223634A1 (en) Peptide deformylase inhibitors
AU2003293556A1 (en) Methods of diagnosing and treating cancer
AU2003285485A1 (en) 5 ANDROSTEN-3Beta-OL STEROID INTERMEDIATES AND PROCESSES FOR THEIR PREPARATION
WO2002061430A3 (en) Methods and reagents for treating autoimmune disorders
MXPA05009428A (en) Compositions and methods for preventing and treating endotoxin-related diseases and conditions.
AU2002258437A1 (en) Peptide deformylase inhibitors
AU2003304490A1 (en) Peptide deformylase inhibitors
AU2003294272A1 (en) Methods for diagnosing the presence or stage of cancer
WO2003099783A3 (en) Tropane compounds